Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.

Fanconi anemia is an inherited cancer predisposition disease characterized by cytogenetic and cellular hypersensitivity to cross-linking agents. Seeking evidence of Fanconi anemia protein dysfunction in women at risk of ovarian cancer, we screened ovarian surface epithelial cells from 25 primary cultures established from 22 patients using cross-linker hypersensitivity assays. Samples were obtained from (a) women at high risk for ovarian cancer with histologically normal ovaries, (b) ovarian cancer patients, and (c) a control group with no family history of breast or ovarian cancer. In chromosomal breakage assays, all control cells were mitomycin C (MMC) resistant, but eight samples (five of the six high-risk and three of the eight ovarian cancer) were hypersensitive. Lymphocytes from all eight patients were MMC resistant. Only one of the eight patients had a BRCA1 germ-line mutation and none had BRCA2 mutations, but FANCD2 was reduced in five of the eight. Ectopic expression of normal FANCD2 cDNA increased FANCD2 protein and induced MMC resistance in both hypersensitive lines tested. No FANCD2 coding region or promoter mutations were found, and there was no genomic loss or promoter methylation in any Fanconi anemia genes. Therefore, in high-risk women with no BRCA1 or BRCA2 mutations, tissue-restricted hypersensitivity to cross-linking agents is a frequent finding, and chromosomal breakage responses to MMC may be a sensitive screening strategy because cytogenetic instability identified in this way antedates the onset of carcinoma. Inherited mutations that result in tissue-specific FANCD2 gene suppression may represent a cause of familial ovarian cancer.

[1]  H. Nelson,et al.  Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement , 2005 .

[2]  H. Katabuchi,et al.  Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis. , 2005, International review of cytology.

[3]  G. Bagby.  Genetic basis of Fanconi anemia , 2003, Current opinion in hematology.

[4]  M. Lensch,et al.  Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemia , 1999, Leukemia.

[5]  K. Offit.  Clinical Cancer Genetics: Risk Counseling and Management , 1998 .

[6]  G. Pals,et al.  X-linked inheritance of Fanconi anemia complementation group B , 2004, Nature Genetics.

[7]  K.-L Xu,et al.  Loss of heterozygosity at chromosome 3p in epithelial ovarian cancer in China , 2001, International Journal of Gynecologic Cancer.

[8]  R. Moses,et al.  Hypersensitivity to oxygen is a uniform and secondary defect in Fanconi anemia cells. , 1993, Mutation research.

[9]  C. Roskelley,et al.  The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer , 2003, Reproductive biology and endocrinology : RB&E.

[10]  M. Walton,et al.  Characterisation of the P53 status, BCL‐2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines , 1998, International journal of cancer.

[11]  M. Grompe,et al.  Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. , 2003, Genes & development.

[12]  G. Woude,et al.  Abnormal Centrosome Amplification in the Absence of p53 , 1996, Science.

[13]  S. Olson,et al.  Cisplatin and the sensitive cell , 2003, Nature Medicine.

[14]  J. Grill,et al.  Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. , 2002, Cancer research.

[15]  B. Johansson,et al.  Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders , 2005, Genes, chromosomes & cancer.

[16]  C. Mathew,et al.  Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors , 2003, Nature Medicine.

[17]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[18]  A. D’Andrea,et al.  A novel diagnostic screen for defects in the Fanconi anemia pathway. , 2002, Blood.

[19]  R. Berkowitz,et al.  Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. , 2000, Gynecologic oncology.

[20]  C. Mathew,et al.  The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J , 2005, Nature Genetics.

[21]  G. Bagby,et al.  FANCC interacts with Hsp70 to protect hematopoietic cells from IFN-gamma/TNF-alpha-mediated cytotoxicity. , 2001, The EMBO journal.

[22]  W. B. Smith,et al.  A Role for Endothelial NO Synthase in LTP Revealed by Adenovirus-Mediated Inhibition and Rescue , 1996, Science.

[23]  M. Inoue,et al.  K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. , 1991, The American journal of pathology.

[24]  T. Richmond,et al.  Analysis of chromosome breakpoints in neuroblastoma at sub‐kilobase resolution using fine‐tiling oligonucleotide array CGH , 2005, Genes, chromosomes & cancer.

[25]  S. Ganesan,et al.  Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. , 2001, Molecular cell.

[26]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[27]  Tracy A Wolff,et al.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. , 2006, American family physician.

[28]  G. Chenevix-Trench,et al.  Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. , 1998, Cancer research.

[29]  D. Beier,et al.  Generation of murine stromal cell lines supporting hematopoietic stem cell proliferation by use of recombinant retrovirus vectors encoding simian virus 40 large T antigen , 1988, Molecular and cellular biology.

[30]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[31]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[32]  Christopher G Mathew,et al.  Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. , 2004, Human molecular genetics.

[33]  D. Näf,et al.  Functional Activity of the Fanconi Anemia Protein FAA Requires FAC Binding and Nuclear Localization , 1998, Molecular and Cellular Biology.

[34]  M. Wigler,et al.  Circular binary segmentation for the analysis of array-based DNA copy number data. , 2004, Biostatistics.

[35]  J. Ott,et al.  The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia , 2005, Nature Genetics.

[36]  A. D’Andrea,et al.  S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. , 2002, Blood.

[37]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[38]  A. D’Andrea,et al.  Carboxy terminal region of the Fanconi anemia protein, FANCG/XRCC9, is required for functional activity. , 2000, Blood.

[39]  J. Schouten,et al.  Methylation-Specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences , 2005, Nucleic acids research.

[40]  J W Gray,et al.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Tashiro,et al.  c‐myc over‐expression in human primary ovarian tumours: Its relevance to tumour progression , 1992, International journal of cancer.

[42]  Hans Joenje,et al.  Biallelic Inactivation of BRCA2 in Fanconi Anemia , 2002, Science.